drug

Semaglutide, 1.34 mg/mL

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Anders Fink-Jensen, MD, DMSci
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

2
Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?
NCT04892199Phase 4Active Not Recruiting
Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes
NCT05193578Phase 2Completed

KOLs & investigators

2
Anders Fink-Jensen, MDKOL score 8
Jan Frystyk, Professor

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Anders Fink-Jensen, MD, DMSci
company
trial
Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?
PHASE4
trial
Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes
PHASE2
trial
indication
Schizophrenia
indication
Prediabetic State
indication
Metabolic Disturbance
indication
Schizophrenia
indication
KOL
Anders Fink-Jensen, MD
KOL score 8
person
Jan Frystyk, Professor
KOL score —
person